Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer
Year: 2019
Type: article
Source: Cancer Research
Authors: Jörn Weisner, Ina Landel, Christoph Reintjes, Niklas Uhlenbrock, Marija Trajkovic-Arsic, Niklas Dienstbier, Julia Hardick, Swetlana Ladigan, Marius Lindemann, Steven Smith, Lena Quambusch, Rebekka Scheinpflug, Laura Depta, Rajesh Gontla, Anke Unger, Heiko Müller, Matthias Baumann, Carsten Schultz-Fademrecht, Georgia Günther, Abdelouahid Maghnouj, Matthias P. Müller, Michael Pohl, Christian Teschendorf, Heiner Wolters, Richard Viebahn, Andrea Tannapfel, Waldemar Uhl, Jan G. Hengstler, Stephan A. Hahn, Jens T. Siveke, Daniel Rauh
Institutions: TU Dortmund University, Ruhr University Bochum, German Cancer Research Center, Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, Lead Discovery Center (Germany), Leibniz Research Centre for Working Environment and Human Factors, Universitätsklinikum Knappschaftskrankenhaus Bochum, St. Josef-Hospital
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2922152201
